CN113260628A - 治疗支气管肺发育不良的抗flt-1抗体 - Google Patents

治疗支气管肺发育不良的抗flt-1抗体 Download PDF

Info

Publication number
CN113260628A
CN113260628A CN201980053845.8A CN201980053845A CN113260628A CN 113260628 A CN113260628 A CN 113260628A CN 201980053845 A CN201980053845 A CN 201980053845A CN 113260628 A CN113260628 A CN 113260628A
Authority
CN
China
Prior art keywords
flt
antibody
binding fragment
antigen
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980053845.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·基弗
J·博斯科
S·艾柏曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetics Therapies Inc filed Critical Shire Human Genetics Therapies Inc
Publication of CN113260628A publication Critical patent/CN113260628A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980053845.8A 2018-06-22 2019-06-21 治疗支气管肺发育不良的抗flt-1抗体 Pending CN113260628A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688541P 2018-06-22 2018-06-22
US62/688,541 2018-06-22
PCT/US2019/038470 WO2019246521A1 (en) 2018-06-22 2019-06-21 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Publications (1)

Publication Number Publication Date
CN113260628A true CN113260628A (zh) 2021-08-13

Family

ID=67211919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053845.8A Pending CN113260628A (zh) 2018-06-22 2019-06-21 治疗支气管肺发育不良的抗flt-1抗体

Country Status (5)

Country Link
US (1) US20210261672A1 (https=)
EP (1) EP3810652A1 (https=)
JP (2) JP2021535896A (https=)
CN (1) CN113260628A (https=)
WO (1) WO2019246521A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026072909A2 (en) * 2024-09-27 2026-04-02 Amgen Inc. Flt1 binding proteins and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292124A (zh) * 2009-01-26 2011-12-21 英特芒尼公司 用于治疗急性心肌梗死和相关疾患的方法
CN107683143A (zh) * 2015-04-07 2018-02-09 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
CN107690335A (zh) * 2015-04-07 2018-02-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292124A (zh) * 2009-01-26 2011-12-21 英特芒尼公司 用于治疗急性心肌梗死和相关疾患的方法
CN107683143A (zh) * 2015-04-07 2018-02-09 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
CN107690335A (zh) * 2015-04-07 2018-02-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARVIND SEHGAL等: ""A New Look at Bronchopulmonary Dysplasia: Postcapillary Pathophysiology and Cardiac Dysfunction"", 《PULMONARY CIRCULATION》, vol. 6, no. 4, pages 508 - 515, XP055625763, DOI: 10.1086/688641 *
BARD, H等: ""Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia"", 《JOURNAL OF PEDIATRICS》, vol. 132, no. 4, pages 630 - 634, XP005692848, DOI: 10.1016/S0022-3476(98)70351-8 *

Also Published As

Publication number Publication date
EP3810652A1 (en) 2021-04-28
JP2023108031A (ja) 2023-08-03
JP2021535896A (ja) 2021-12-23
WO2019246521A1 (en) 2019-12-26
US20210261672A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US8119134B2 (en) Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
CN108137683A (zh) 生物医药组合物
US20200362041A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
AU2024227035A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
KR20210044742A (ko) 건선 치료용 조성물 및 방법
JP2023108031A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体
JP2023507795A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
CA2982815C (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
WO2007037788A1 (en) Antibody composition and passive immunization against pregnancy-induced hypertension using antidigoxin antibody (digibind)
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
BR112017021416B1 (pt) Uso de um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813